Lareb Intensive Monitoring

Lareb Intensive Monitoring (LIM) is a new method in monitoring pharmacovigilance. LIM is observing and following patients and their experiences with a new drug for a certain period.

Experiences of patients centralised 

LIM monitors the use of some new drugs from the moment the patient uses the first prescription. The patients get an information brochure with an invitation to participate in the study which is given by their pharmacy. This brochure contains a registration code. With this code the patients are able to make a registration for the LIM-research via the website: www.larebmonitor.nl. 

It is important that this registration happens as soon as possible. Then we are able to monitor the side effects of the drug from the first use. The patient receives a notification from us several times via e-mail for filling in a short online questionnaire. This study allows us to get a quick insight about the study drug.

Lareb and LIM! 

With Lareb Intensive Monitoring it is possible to detect side effects of drugs, especially new drugs, at an early stage. LIM is a complement to the current way of working and does not replace reporting significant observations by the healthcare professionals or patient.

Want more information? 

The website of Lareb Intensive monitoring provides more information about the study, the drugs that are monitored and how you can register as a caregiver or patient. You will also find the results of earlier studies and the latest news. The most information is in Dutch only.

The most recent publication of LIM is published in Pharmacoepidemiology and Drug Safety (May 2011). You can download the publication here.